Protocol

Cancer Nanotechnology

Volume 624 of the series Methods in Molecular Biology pp 375-384

Date:

Colloidal Gold: A Novel Nanoparticle for Targeted Cancer Therapeutics

  • Anathea C. PowellAffiliated withTumor Angiogenesis Section, Surgery Branch, National Cancer Institute
  • , Giulio F. PaciottiAffiliated withCytImmune Sciences, Inc.
  • , Steven K. LibuttiAffiliated withTumor Angiogenesis Section, Surgery Branch, National Cancer Institute

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Since their initial description in 1857, gold nanoparticles have been used extensively in the fields of diagnostics and therapeutics. Now, gold nanoparticles are engineered to target the delivery of potent anti-cancer therapeutics to solid tumors to improve either their safety or efficacy or both. Described in this chapter is the development of one such nanotherapeutic, termed CYT-6091, that targets the delivery of tumor necrosis factor alpha (TNF) to solid tumors. Outlined in the presentation is a discussion of nanoparticles and specifically colloidal gold, an historical review on the biology of TNF and its limited use in the clinic when administered systemically, and finally, how gold nanoparticles bound with TNF may improve the safety and efficacy profiles of TNF.

Key words

Tumor necrosis factor colloidal gold colloidal gold nanoparticles pegylated colloidal gold tumor necrosis factor conjugated to colloidal gold